Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Novaliq GmbH has 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 5 distinct examiners across 5 distinct art units. Jeffrey T Palenik is the busiest examiner, with 2 of the 6 pending actions currently assigned to them.
Since there are 5 examiners for 6 actions, most examiners are only reviewing one case for the company. The spread across 5 art units suggests that the pending innovations are being evaluated by several different specialized technical divisions. Practitioners must manage the 2 actions under Jeffrey T Palenik while navigating the requirements of the other examiners. This distribution of 6 actions ensures that a variety of perspectives are applied to the company's biotechnology and pharmaceutical applications. The involvement of 5 art units requires a prosecution approach that can adapt to the specific standards of multiple technical departments. With 5 distinct examiners involved, the company must maintain consistent arguments while addressing the individual preferences of each reviewer. This structure provides a diverse but manageable prosecution landscape for the company's current pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (17%) |
| Double-patenting + other | 3 (50%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALENIK, JEFFREY T | 2 | 53.5% | +27.0% |
| YU, HONG | 1 | 31.1% | +5.7% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +36.1% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.6% | +62.3% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18784569 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | PALENIK, JEFFREY T | — |
| 17751512 | SUSPENSION COMPRISING A PROTEIN PARTICLE SUSPENDED IN A NON-AQUEOUS VEHICLE | HOERNER, PAUL ELLSWORTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17350427 | SEMIFLUORINATED COMPOUNDS | MOU, LIYUAN | 25d overdue |
| 19540268 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | PALENIK, JEFFREY T | — |
| 18897877 | SEMIFLUORINATED COMPOUNDS AND THEIR COMPOSITIONS | PECKHAM, RICHARD GRANT | — |
| 18784569 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | PALENIK, JEFFREY T | — |
| 17751512 | SUSPENSION COMPRISING A PROTEIN PARTICLE SUSPENDED IN A NON-AQUEOUS VEHICLE | HOERNER, PAUL ELLSWORTH | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1614 | 1 |
| 1627 | 1 |
| 1611 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19540268 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | PALENIK, JEFFREY T | 1615 | §102Other | Final Rejection | — | Pending | Feb 13, 2026 |
| 19274087 | O/W-EMULSIONS COMPRISING SEMIFLUORINATED ALKANES | YU, HONG | 1614 | §103§112DP | Non-Final OA | — | Pending | Jul 18, 2025 |
| 18897877 | SEMIFLUORINATED COMPOUNDS AND THEIR COMPOSITIONS | PECKHAM, RICHARD GRANT | 1627 | §112DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18784569 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | PALENIK, JEFFREY T | 1615 | §103§112Other | Non-Final OA | — | Pending | Jul 25, 2024 |
| 17751512 | SUSPENSION COMPRISING A PROTEIN PARTICLE SUSPENDED IN A NON-AQUEOUS VEHICLE | HOERNER, PAUL ELLSWORTH | 1611 | §103§112 | Non-Final OA | — | Pending | May 23, 2022 |
| 17350427 | SEMIFLUORINATED COMPOUNDS | MOU, LIYUAN | 1628 | §103DP | Final Rejection | 25d overdue | Pending | Jun 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNovaliq GmbH has 6 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Jeffrey T Palenik has the most, with 2 of Novaliq GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
